Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma

Oncogene

Volumn 30, Issue 46, 2011, Pages 4666-4677

  Watt, S A ^a   Pourreyron, C ^a   Purdie, K ^b   Hogan, C ^a   Cole, C L ^a   Foster, N ^c   Pratt, N ^c   Bourdon, J C ^a   Appleyard, V ^a   Murray, K ^a   Thompson, A M ^a   Mao, X ^b   Mein, C ^b   Bruckner Tuderman, L ^d   Evans, A ^c   McGrath, J A ^e   Proby, C M ^a   Foerster, J ^a   Leigh, I M ^a   South, A P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF FREIBURG   (Germany)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

cutaneous squamous cell carcinoma; gene expression analysis; PLK1; primary cell culture; therapeutic targets

Indexed keywords

MESSENGER RNA; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL CYCLE PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINOCYTES; MOLECULAR TARGETED THERAPY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 81255137880     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.180     Document Type: Article

References (56)

1. Bertram MJ, Pereira-Smith OM. (2001). Conservation of the MORF4 related gene family: identification of a new chromo domain subfamily and novel protein motif. Gene 266: 111-121. (Pubitemid 32268662)
2. Braakhuis BJ, Brakenhoff RH, Leemans CR. (2010). Gene expression profiling in head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg 18: 67-71.
3. Brattain MG, Brattain DE, Fine WD, Khaled FM, Marks ME, Kimball PM et al. (1981). Initiation and characterization of cultures of human colonic carcinoma with different biological characteristics utilizing feeder layers of confluent fibroblasts. Oncodev Biol Med 2: 355-366. (Pubitemid 12163670)
4. Burns JE, Baird MC, Clark LJ, Burns PA, Edington K, Chapman C et al. (1993). Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer 67: 1274-1284. (Pubitemid 23172865)
5. Cai Y, Jin J, Tomomori-Sato C, Sato S, Sorokina I, Parmely TJ et al. (2003). Identification of new subunits of the multiprotein mammalian TRRAP/TIP60-containing histone acetyltransferase complex. J Biol Chem 278: 42733-42736. (Pubitemid 37345881)
6. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA et al. (2009). Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58: 79-89.
7. Cheng H, Force T. (2010). Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106: 21-34.
8. Creighton C, Kuick R, Misek DE, Rickman DS, Brichory FM, Rouillard JM et al. (2003). Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol 4: R46.
9. Cunningham J, Sales M, Pearce A, Howard J, Stallings R, Telford N et al. (2002). Does isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome? Br J Haematol 119: 1062-1069. (Pubitemid 35463834)
10. Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS. (2004). A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 5: 47.
11. Degenhardt Y, Lampkin T. (2010). Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16: 384-389.
12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037. (Pubitemid 32267972)
13. Edgar R, Domrachev M, Lash AE. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210. (Pubitemid 34679544)
14. Epstein Sr E. (1984). Metastases of sun-induced SCC. J Dermatol Surg Oncol 10: 418.
15. Euvrard S, Kanitakis J, Claudy A. (2003). Skin cancers after organ transplantation. N Engl J Med 348: 1681-1691. (Pubitemid 36459475)
16. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. (2009). Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol 60: 203-211.
17. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
18. Giglia-Mari G, Sarasin A. (2003). TP53 mutations in human skin cancers. Hum Mutat 21: 217-228. (Pubitemid 36292964)
19. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E et al. (2010). Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 70: 1513-1523.
20. Gu W, Roeder RG (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606. (Pubitemid 27357952)
21. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. (2005). Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65: 2698-2704. (Pubitemid 40490070)
22. Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J et al. (2006). Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 126: 869-881.
23. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
24. Hayakawa T, Ohtani Y, Hayakawa N, Shinmyozu K, Saito M, Ishikawa F et al. (2007). RBP2 is an MRG15 complex component and downregulates intragenic histone H3 lysine 4 methylation. Genes Cells 12: 811-826. (Pubitemid 46952553)
25. Liu X, Lei M, Erikson RL. (2006). Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26: 2093-2108. (Pubitemid 43346913)
26. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408. (Pubitemid 34164012)
27. Masters JR. (2000). Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol 1: 233-236.
28. Merlo LM, Pepper JW, Reid BJ, Maley CC. (2006). Cancer as an evolutionary and ecological process. Nat Rev Cancer 6: 924-935. (Pubitemid 44862677)
29. Nindl I, Dang C, Forschner T, Kuban RJ, Meyer T, Sterry W et al. (2006). Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 5: 30.
30. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565-577. (Pubitemid 29268440)
31. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT et al. (1999). Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217. (Pubitemid 29374734)
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672. (Pubitemid 41464705)
33. Purdie KJ, Harwood CA, Gulati A, Chaplin T, Lambert SR, Cerio R et al. (2009). Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol 129: 1562-1568.
34. Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M et al. (2007). Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer 46: 661-669. (Pubitemid 46802333)
35. Rheinwald JG, Beckett MA. (1981). Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 41: 1657-1663. (Pubitemid 11114553)
36. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C et al. (2008). The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
37. Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J. (2010). Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One 5: e9701.
38. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P et al. (2000). Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235. (Pubitemid 30132189)
39. Schmit TL, Ahmad N. (2007). Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther 6: 1920-1931. (Pubitemid 47052482)
40. Schmit TL, Zhong W, Nihal M, Ahmad N. (2009a). Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 8: 2697-2702.
41. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. (2009b). Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 129: 2843-2853.
42. Schoffski P. (2009). Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559-570.
43. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A et al. (2008). Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 47: 755-765.
44. Sharma SV, Haber DA, Settleman J. (2010). Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10: 241-253.
45. Smith HS, Lan S, Ceriani R, Hackett AJ, Stampfer MR. (1981). Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. Cancer Res 41: 4637-4643. (Pubitemid 12201385)
46. South AP, Wan H, Stone MG, Dopping-Hepenstal PJ, Purkis PE, Marshall JF et al. (2003). Lack of plakophilin 1 increases keratinocyte migration and reduces desmosome stability. J Cell Sci 116: 3303-3314. (Pubitemid 37038979)
47. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. (2006). Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 184: 6-10. (Pubitemid 43149790)
48. Suiqing C, Min Z, Lirong C. (2005). Overexpression of phosphory-lated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 32: 354-360. (Pubitemid 40874460)
49. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. (2005). Polo-like kinases (Plks) and cancer. Oncogene 24: 287-291. (Pubitemid 40188609)
50. Van Haren R, Feldman D, Sinha AA. (2009). Systematic comparison of nonmelanoma skin cancer microarray datasets reveals lack of consensus genes. Br J Dermatol 161: 1278-1287.
51. Veness MJ, Porceddu S, Palme CE, Morgan GJ. (2007). Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 29: 621-631. (Pubitemid 47168232)
52. Wallis S, Lloyd S, Wise I, Ireland G, Fleming TP, Garrod D. (2000). The alpha isoform of protein kinase C is involved in signaling the response of desmosomes to wounding in cultured epithelial cells. Mol Biol Cell 11: 1077-1092. (Pubitemid 30159323)
53. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C et al. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137: 231-245. (Pubitemid 27167310)
54. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA et al. (2001). Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61: 5974-5978. (Pubitemid 32762523)
55. Wu K, Bonavida B. (2009). The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 29: 241-254.
56. Yamaguchi K, Sakai M, Shimokawa T, Yamada Y, Nakamura Y, Furukawa Y. (2010). C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer. Br J Cancer 102: 325-331.